NYSE:MTAL
NYSE:MTALMetals and Mining

Is MAC Copper Poised for Growth After New Infrastructure Fund Announcement?

Thinking about what to do with MAC Copper stock? You are not alone. The company’s recent price trajectory has caught the eye of both cautious investors and optimistic speculators. In the last year, the stock slipped by 12.2%, but look further back and the story changes. MAC Copper is still up 24.4% over the last three years and an impressive 15.7% so far this year. If you have been watching for signs of life after a slow month or two, the near-flat 30-day and 7-day returns show the market...
NasdaqGM:GCMG
NasdaqGM:GCMGCapital Markets

How Will Recent Private Markets Growth Shape GCM Grosvenor’s Valuation in 2025?

Thinking about what to do with GCM Grosvenor stock? You are not alone. Whether you are holding, buying, or considering taking your gains elsewhere, there is plenty to weigh here. GCM Grosvenor’s stock has had an interesting ride lately, giving investors both reasons for optimism and a few for caution. This past week, shares dipped slightly by 0.7%. Looking at the last 30 days, the slide has been a steeper 6.2%. Year-to-date, the price is down 4.1%. From a one-year perspective, things look...
NasdaqGS:FSUN
NasdaqGS:FSUNBanks

FirstSun Capital Bancorp (FSUN): Is Strong Growth Fueling an Undervalued Opportunity?

FirstSun Capital Bancorp (FSUN) has recently seen a wave of attention after reports spotlighted its strong net interest income growth, improved operational efficiency, and substantial tangible book value gains. See our latest analysis for FirstSun Capital Bancorp. While the boost in net interest income and improved efficiency have made headlines, FirstSun Capital Bancorp’s recent share price hasn’t reflected a major shift. However, its three-year total shareholder return of 28% suggests...
NasdaqCM:OVID
NasdaqCM:OVIDBiotechs

Ovid Therapeutics (OVID): Evaluating Valuation After Positive Phase 1 Trial Results and $175 Million Financing

Ovid Therapeutics has grabbed investor attention after unveiling encouraging Phase 1 results for its next-generation epilepsy drug, OV329. In addition to the promising data, the company secured $175 million in new financing, extending its cash runway. See our latest analysis for Ovid Therapeutics. After surging on the back of positive Phase 1 data and a major private financing announcement, Ovid Therapeutics has seen renewed bullishness, with momentum building over the short term. While the...
NYSE:MMI
NYSE:MMIReal Estate

What Do Recent Losses Mean for Marcus & Millichap Stock in 2025?

If you’ve been wondering whether now is the right time to buy, sell, or just keep an eye on Marcus & Millichap stock, you’re not alone. The real estate services company has had a bumpy ride recently, and investors are looking for direction. After closing at $28.89, Marcus & Millichap has moved down 2.4% in the past week, dropping 12.8% over the last month, and showing a year-to-date loss of 22.8%. Even over the past twelve months, shares are down 18.1%, although the five-year story is just...
NYSE:BDC
NYSE:BDCElectronic

Does the Recent Share Pullback Offer a Fresh Opportunity in Belden for 2025?

Trying to figure out what to do with Belden stock right now? You are not alone. After all, in the past month the stock slid down 9.1%, and even pulled back 2.2% just in the last week. But context is everything. Zoom out, and you will see that Belden has actually returned 4.2% year-to-date, and an impressive 247.3% over the last five years. That kind of long-term growth can be hard to ignore, and it is making investors wonder if these recent dips are a buying opportunity or a warning sign. So,...
NYSE:BRX
NYSE:BRXRetail REITs

Can Brixmor’s Stable Cash Flow Support Its Value After a 4.6% Monthly Dip in 2025?

If you own shares of Brixmor Property Group or are thinking about adding it to your watchlist, you might be feeling a bit uncertain about the next move. The stock has seen some mild turbulence recently, slipping 2.0% in the past week and down 4.6% over the last month. Year-to-date, it’s off by 2.3%, but zoom out and the picture looks much more optimistic. The stock has gained 2.9% over the past year and 66.6% over three years. Looking back even further, the five-year return sits at a robust...
NasdaqGS:TCOM
NasdaqGS:TCOMHospitality

Does Trip.com Group Offer Growth Potential for 2025 After Strong Earnings Momentum?

Trying to figure out what to do with Trip.com Group stock? You are not alone. It is a name that keeps popping up for investors searching for growth, resilience, and potential bargains in the travel sector. Over the past year, Trip.com Group’s journey has been anything but boring. Yes, the stock dipped 3.7% in the last week, but if you zoom out, it is up 0.7% over the past month and 13.2% since the start of the year. In fact, if you were holding shares for the last three or even five years,...
NYSE:WDH
NYSE:WDHInsurance

Will Waterdrop's (WDH) Profit Reinvestment Strategy Redefine Its Long-Term Growth Narrative?

In the past three months, Waterdrop (NYSE:WDH) experienced strong share market momentum, supported by a 65% increase in net income over the last five years despite return on equity lagging the industry average. Management’s choice to reinvest a high proportion of profits signals a focus on business expansion, even as analysts anticipate earnings growth to moderate going forward. We'll explore how Waterdrop's emphasis on reinvestment and earnings growth could reshape its investment narrative...